This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quinn, J. M. Articles by Martin, T. Search for Related Content PubMed PubMed Citation Articles by Quinn, J. M. Articles by Martin, T.

A Combination of Osteoclast Differentiation Factor and Macrophage-Colony Stimulating Factor Is Sufficient for both Human and Mouse Osteoclast Formation in Vitro

The University of Melbourne, Department of Medicine and St. Vincent’s Institute of Medical Research, Fitzroy, Australia.

Address all correspondence and requests for reprints to: Julian M. W. Quinn, The University of Melbourne, Department of Medicine & St. Vincent’s Institute of Medical Research, 41 Victoria Parade, Melbourne 3065, Australia.

Both human and murine osteoclasts can be derived in vitro from hematopoietic cells or monocytes that are cocultured with osteoblasts or marrow-derived stromal cells. The osteoclastogenic stimulus provided by murine osteoblasts and marrow-derived stromal cells is now known to be mediated by osteoclast differentiation factor (ODF), a membrane-bound tumor necrosis factor-related ligand. This study demonstrates that mouse spleen cells and monocytes form osteoclasts when cultured in the presence of macrophage-colony stimulating factor (M-CSF) and a soluble form of murine ODF (sODF). Numerous multinucleated osteoclasts expressing tartrate resistant acid phosphatase (TRAP) and calcitonin receptor (CTR) formed within 7 days of culture and engaged in extensive lacunar bone resorption. Osteoclast number and bone resorption area was dependent on sODF concentration. Long-term cultured human monocytes also formed bone resorbing osteoclasts in response to co-stimulation by sODF and M-CSF, although this required more than 11 days in culture. This human osteoclast differentiation was strongly inhibited by granulocyte-macrophage colony stimulating factor. This study further characterises murine osteoclast differentiation caused by sODF and M-CSF co-stimulation in vitro, and shows that the same co-stimulation causes human osteoclast differentiation to occur. We propose that this methodology can be employed to investigate the direct effects of cytokines and other factors on human osteoclast differentiation.

This article has been cited by other articles:

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				B. Edderkaoui, D. J. Baylink, W. G. Beamer, J. E. Wergedal, R. Porte, A. Chaudhuri, and S. Mohan Identification of mouse Duffy Antigen Receptor for Chemokines (Darc) as a BMD QTL gene Genome Res., May 1, 2007; 17(5): 577 - 585. [Abstract] [Full Text] [PDF]

				Y.-L. Lin, W. J. S. de Villiers, B. Garvy, S. R. Post, T. R. Nagy, F. F. Safadi, M. C. Faugere, G. Wang, H. H. Malluche, and J. P. Williams The Effect of Class A Scavenger Receptor Deficiency in Bone J. Biol. Chem., February 16, 2007; 282(7): 4653 - 4660. [Abstract] [Full Text] [PDF]

				Y. Tanaka, M. Abe, M. Hiasa, A. Oda, H. Amou, A. Nakano, K. Takeuchi, K. Kitazoe, S. Kido, D. Inoue, et al. Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin Clin. Cancer Res., February 1, 2007; 13(3): 816 - 823. [Abstract] [Full Text] [PDF]

				A. Bronisz, S. M. Sharma, R. Hu, J. Godlewski, G. Tzivion, K. C. Mansky, and M. C. Ostrowski Microphthalmia-associated Transcription Factor Interactions with 14-3-3 Modulate Differentiation of Committed Myeloid Precursors Mol. Biol. Cell, September 1, 2006; 17(9): 3897 - 3906. [Abstract] [Full Text] [PDF]

				J. L. Fisher, R. J. Thomas-Mudge, J. Elliott, D. K. Hards, N. A. Sims, J. Slavin, T. J. Martin, and M. T. Gillespie Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res., April 1, 2006; 66(7): 3620 - 3628. [Abstract] [Full Text] [PDF]

				B. Nardelli, L. Zaritskaya, W. McAuliffe, Y. Ni, C. Lincoln, Y. H. Cho, C. E. Birse, W. Halpern, S. Ullrich, and P. A. Moore Osteostat/Tumor Necrosis Factor Superfamily 18 Inhibits Osteoclastogenesis and Is Selectively Expressed by Vascular Endothelial Cells Endocrinology, January 1, 2006; 147(1): 70 - 78. [Abstract] [Full Text] [PDF]

				H. Shibata, M. Abe, K. Hiura, J. Wilde, K. Moriyama, T. Sano, K.-i. Kitazoe, T. Hashimoto, S. Ozaki, S. Wakatsuki, et al. Malignant B-Lymphoid Cells with Bone Lesions Express Receptor Activator of Nuclear Factor-{kappa}B Ligand and Vascular Endothelial Growth Factor to Enhance Osteoclastogenesis Clin. Cancer Res., September 1, 2005; 11(17): 6109 - 6115. [Abstract] [Full Text] [PDF]

				S. Trudel, Z. H. Li, E. Wei, M. Wiesmann, H. Chang, C. Chen, D. Reece, C. Heise, and A. K. Stewart CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma Blood, April 1, 2005; 105(7): 2941 - 2948. [Abstract] [Full Text] [PDF]

				A. C.W. Zannettino, A. N. Farrugia, A. Kortesidis, J. Manavis, L. B. To, S. K. Martin, P. Diamond, H. Tamamura, T. Lapidot, N. Fujii, et al. Elevated Serum Levels of Stromal-Derived Factor-1{alpha} Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients Cancer Res., March 1, 2005; 65(5): 1700 - 1709. [Abstract] [Full Text] [PDF]

				A. M. Sorkin, K. C. Dee, and M. L. Knothe Tate "Culture shock" from the bone cell's perspective: emulating physiological conditions for mechanobiological investigations Am J Physiol Cell Physiol, December 1, 2004; 287(6): C1527 - C1536. [Abstract] [Full Text] [PDF]

				M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood, October 15, 2004; 104(8): 2484 - 2491. [Abstract] [Full Text] [PDF]

				T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification Endocr. Rev., August 1, 2004; 25(4): 629 - 672. [Abstract] [Full Text] [PDF]

				A. Crisafulli, D. Altavilla, G. Squadrito, A. Romeo, E. B. Adamo, R. Marini, M. A. Inferrera, H. Marini, A. Bitto, R. D'anna, et al. Effects of the Phytoestrogen Genistein on the Circulating Soluble Receptor Activator of Nuclear Factor {kappa}B Ligand-Osteoprotegerin System in Early Postmenopausal Women J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 188 - 192. [Abstract] [Full Text] [PDF]

				T. C. Polek, M. Talpaz, B. G. Darnay, and T. Spivak-Kroizman TWEAK Mediates Signal Transduction and Differentiation of RAW264.7 Cells in the Absence of Fn14/TweakR: EVIDENCE FOR A SECOND TWEAK RECEPTOR J. Biol. Chem., August 22, 2003; 278(34): 32317 - 32323. [Abstract] [Full Text] [PDF]

				J. Paloneva, J. Mandelin, A. Kiialainen, T. Bohling, J. Prudlo, P. Hakola, M. Haltia, Y. T. Konttinen, and L. Peltonen DAP12/TREM2 Deficiency Results in Impaired Osteoclast Differentiation and Osteoporotic Features J. Exp. Med., August 18, 2003; 198(4): 669 - 675. [Abstract] [Full Text] [PDF]

				N. A. McHugh, H. M. Vercesi, R. W. Egan, and J. A. Hey Receptor activator of NF-{kappa}B ligand arrests bone growth and promotes cortical bone resorption in growing rats J Appl Physiol, August 1, 2003; 95(2): 672 - 676. [Abstract] [Full Text] [PDF]

				W. Zou, A. Amcheslavsky, and Z. Bar-Shavit CpG Oligodeoxynucleotides Modulate the Osteoclastogenic Activity of Osteoblasts via Toll-like Receptor 9 J. Biol. Chem., May 2, 2003; 278(19): 16732 - 16740. [Abstract] [Full Text] [PDF]

				A. Gurlek, M. R. Pittelkow, and R. Kumar Modulation of Growth Factor/Cytokine Synthesis and Signaling by 1{alpha},25-Dihydroxyvitamin D3: Implications in Cell Growth and Differentiation Endocr. Rev., December 1, 2002; 23(6): 763 - 786. [Abstract] [Full Text] [PDF]

				T. Hirayama, L. Danks, A. Sabokbar, and N. A. Athanasou Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis Rheumatology, November 1, 2002; 41(11): 1232 - 1239. [Abstract] [Full Text] [PDF]

				S.D. Neale, E. Schulze, R. Smith, and N.A. Athanasou The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease QJM, April 1, 2002; 95(4): 233 - 240. [Abstract] [Full Text] [PDF]

				W. ZOU, H. SCHWARTZ, S. ENDRES, G. HARTMANN, and Z. BAR-SHAVIT CpG oligonucleotides: novel regulators of osteoclast differentiation FASEB J, March 1, 2002; 16(3): 274 - 282. [Abstract] [Full Text] [PDF]

				N. R. Jorgensen, Z. Henriksen, O. H. Sorensen, E. F. Eriksen, R. Civitelli, and T. H. Steinberg Intercellular Calcium Signaling Occurs between Human Osteoblasts and Osteoclasts and Requires Activation of Osteoclast P2X7 Receptors J. Biol. Chem., February 22, 2002; 277(9): 7574 - 7580. [Abstract] [Full Text] [PDF]

				S. Wei, M. W.-H. Wang, S. L. Teitelbaum, and F. P. Ross Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-kappa B and Mitogen-activated Protein Kinase Signaling J. Biol. Chem., February 15, 2002; 277(8): 6622 - 6630. [Abstract] [Full Text] [PDF]

				K. Itoh, N. Udagawa, T. Katagiri, S. Iemura, N. Ueno, H. Yasuda, K. Higashio, J. M. W. Quinn, M. T. Gillespie, T. J. Martin, et al. Bone Morphogenetic Protein 2 Stimulates Osteoclast Differentiation and Survival Supported by Receptor Activator of Nuclear Factor-{kappa}B Ligand Endocrinology, August 1, 2001; 142(8): 3656 - 3662. [Abstract] [Full Text] [PDF]

				S. Wei, S. L. Teitelbaum, M. W.-H. Wang, and F. P. Ross Receptor Activator of Nuclear Factor-{{kappa}}B Ligand Activates Nuclear Factor-{{kappa}}B in Osteoclast Precursors Endocrinology, March 1, 2001; 142(3): 1290 - 1295. [Abstract] [Full Text] [PDF]

				M. Pfaff and P. Jurdic Podosomes in osteoclast-like cells: structural analysis and cooperative roles of paxillin, proline-rich tyrosine kinase 2 (Pyk2) and integrin {alpha}V{beta}3 J. Cell Sci., January 8, 2001; 114(15): 2775 - 2786. [Abstract] [Full Text] [PDF]

				T. Miyamoto, F. Arai, O. Ohneda, K. Takagi, D. M. Anderson, and T. Suda An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand Blood, December 15, 2000; 96(13): 4335 - 4343. [Abstract] [Full Text] [PDF]

				F. Gori, L. C. Hofbauer, C. R. Dunstan, T. C. Spelsberg, S. Khosla, and B. L. Riggs The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated Endocrinology, December 1, 2000; 141(12): 4768 - 4776. [Abstract] [Full Text] [PDF]

				E. A. Gonzalez The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy Nephrol. Dial. Transplant., July 1, 2000; 15(7): 945 - 950. [Full Text] [PDF]

				L. C. Hofbauer and A. E. Heufelder The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2355 - 2363. [Full Text]

				X. Li, Y. Okada, C. C. Pilbeam, J. A. Lorenzo, C. R. J. Kennedy, R. M. Breyer, and L. G. Raisz Knockout of the Murine Prostaglandin EP2 Receptor Impairs Osteoclastogenesis in Vitro Endocrinology, June 1, 2000; 141(6): 2054 - 2061. [Abstract] [Full Text] [PDF]

				I Itonaga, A Sabokbar, D W Murray, and N A Athanasou Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages Ann Rheum Dis, January 1, 2000; 59(1): 26 - 31. [Abstract] [Full Text]

				F. Arai, T. Miyamoto, O. Ohneda, T. Inada, T. Sudo, K. Brasel, T. Miyata, D. M. Anderson, and T. Suda Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of c-Fms and Receptor Activator of Nuclear Factor {kappa}B (RANK) Receptors J. Exp. Med., December 20, 1999; 190(12): 1741 - 1754. [Abstract] [Full Text] [PDF]

				M. Mannstadt, H. Juppner, and T. J. Gardella Receptors for PTH and PTHrP: their biological importance and functional properties Am J Physiol Renal Physiol, November 1, 1999; 277(5): F665 - F675. [Abstract] [Full Text] [PDF]

				L. C. Hofbauer, F. Gori, B. L. Riggs, D. L. Lacey, C. R. Dunstan, T. C. Spelsberg, and S. Khosla Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis Endocrinology, October 1, 1999; 140(10): 4382 - 4389. [Abstract] [Full Text]

				R. J. Thomas, T. A. Guise, J. J. Yin, J. Elliott, N. J. Horwood, T. J. Martin, and M. T. Gillespie Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation Endocrinology, October 1, 1999; 140(10): 4451 - 4458. [Abstract] [Full Text]

				S.-K. Lee and J. A. Lorenzo Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with Osteoclast-Like Cell Formation Endocrinology, August 1, 1999; 140(8): 3552 - 3561. [Abstract] [Full Text]

				T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M. T. Gillespie, and T. J. Martin Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families Endocr. Rev., June 1, 1999; 20(3): 345 - 357. [Abstract] [Full Text]

				K. Thirunavukkarasu, D. L. Halladay, R. R. Miles, X. Yang, R. J. S. Galvin, S. Chandrasekhar, T. J. Martin, and J. E. Onyia The Osteoblast-specific Transcription Factor Cbfa1 Contributes to the Expression of Osteoprotegerin, a Potent Inhibitor of Osteoclast Differentiation and Function J. Biol. Chem., August 11, 2000; 275(33): 25163 - 25172. [Abstract] [Full Text] [PDF]

				H. Zhou, V. Kartsogiannis, Y. S. Hu, J. Elliott, J. M. W. Quinn, W. J. McKinstry, M. T. Gillespie, and K. W. Ng A Novel Osteoblast-derived C-type Lectin That Inhibits Osteoclast Formation J. Biol. Chem., April 27, 2001; 276(18): 14916 - 14923. [Abstract] [Full Text] [PDF]